Novo Nordisk A/S Sponsored ADR (NVO)
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in obesity drug trial
Eli Lilly and Co (NYSE:LLY)'s weight loss drug Zepbound (tirzepatide) has shown superior results compared to Novo Nordisk (NYSE:NVO)'s Wegovy (semaglutide) in a direct clinical trial, marking the first head-to-head comparison between the two leading obesity treatments. In the 72-week SURMOUNT-5 trial, participants on Zepbound lost an average of about 50 pounds (22.8 kg), equating to approximately 20.2% of their body weight.
Novo Nordisk Stock Is Slumping Today. Here's Why.
Shares of the Ozempic-maker fell while the rest of the market rose,as it's facing a hit to revenue from different directions.
Novo Nordisk: Nothing Has Changed, Except That It's Cheaper Now
Despite Novo Nordisk's stock decline, the company's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. Eli Lilly's oral weight-loss drug announcement caused undue panic; NVO's advanced pipeline, including oral semaglutide and Amycretin, remains highly competitive. The partnership with Hims & Hers mitigates legal risks and boosts distribution, promising significant synergies and long-term benefits for the Company.
Novo Nordisk: It's Not Been This Cheap For Many Years
Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Despite setbacks, Novo is actively enhancing market access for Wegovy and partnering with CVS and telehealth platforms to regain momentum. NVO's valuation is at a multi-year low, pointing to a plausible recovery if it manages to improve its execution and stem further losses.
Novo Nordisk (NVO) Upgraded to Buy: Here's What You Should Know
Novo Nordisk (NVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Novo Nordisk (NVO) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Does Novo Nordisk (NVO) Have the Potential to Rally 51.24% as Wall Street Analysts Expect?
The consensus price target hints at a 51.2% upside potential for Novo Nordisk (NVO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers
One day after WeightWatchers said that it would file for bankruptcy, weight-loss drug giant Novo Nordisk's outlook is brightening.
Novo Nordisk A/S (NVO) Q1 2025 Earnings Call Transcript
Novo Nordisk A/S (NVO) Q1 2025 Results Conference Call May 7, 2025 7:00 AM ET Company Participants Jacob Rode - Head of Investor Relations Lars Jorgensen - President and Chief Executive Officer David Moore - Executive Vice President, U.S. Operations and Global Business Development Mike Doustdar - Executive VP of International Operations Martin Holst Lange - Executive Vice President and Head of Development Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer Conference Call Participants Richard Vosser - JPMorgan Chase & Co. James Quigley - Goldman Sachs Peter Verdault - BNP Paribas Martin Parkhoi - SEB Michael Nedelcovych - TD Cowen Sachin Jain - Bank of America Merrill Lynch Jo Walton - UBS Operator Good day, and thank you for standing by. Welcome to the Q1 2025 Novo Nordisk A/S Earnings Conference Call.
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up
NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.
Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype
Novo Nordisk A/S announced its Q1 earnings today, blaming a slight revenue miss on sales of compounded semaglutide. Q1 2025 earnings showed revenue of ~$11.9bn, operating profit of $5.9bn, with diluted EPS up 15% year-on-year. ~65% of revenues were driven by semaglutide, or Wegovy (obesity)/Ozempic (diabetes). This is truly a miraculous drug, and as compounded versions of semaglutide cease to be manufactured, performance will improve in 2H25.
Novo Nordisk investors relieved after expected guidance cut
Novo Nordisk (NYSE:NVO) first-quarter results offered few surprises, but they may just have delivered the market something it needed more: relief. That collective anxiety release was reflected in the share price, which rose 4%.
